Advertisement

Topics

Foamix Ltd Company Profile

17:30 EST 14th December 2018 | BioPortfolio

Foamix Ltd. is a leading developer of topical and mucosal foams for dermatological and gynecological applications. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is currently collaborating with pharmaceutical and cosmetic companies on a range of projects in the development of proprietary dermatological and gynecologic foam products. Additionally, the Company has an in-house pipeline of dermatological and gynecological formulations in foam presentation. Foamix's psoriasis foam product licensed to Dr. Reddy's Laboratories and marketed by Promius Pharma under the trade mark Scytera(TM) was launched in the United States in early 2009.


News Articles [42 Associated News Articles listed on BioPortfolio]

Foamix plans $70m offering after acne trial success

Foamix Pharmaceuticals intends to market its acne treatment by itself.

Foamix Phase III papulopustular rosacea trials meet endpoints

Foamix Pharmaceuticals has reported positive top-line results from the Phase III programme of FMX103 1.5% minocycline foam being assessed for moderate-to-severe...Read More... The post Foamix Phase I...

Foamix completes dosing in FX2016-11 and FX2016-12 studies

Foamix Pharmaceuticals has completed patient enrolment and dosing in the FX2016-11 and FX2016-12 studies designed to treat moderate-to-severe papulopustular rosacea....Read More... The post Foamix com...

Foamix publishes top line phase III results for rosacea drug

Clinical stage dermatology-focused Foamix Pharmaceuticals has announced top line results from a phase III study into its FMX103, which is...Read More... The post Foamix publishes top line phase III re...

Foamix’s rosacea drug FMX103 splits views on sunburn risk

Foamix Pharmaceuticals’ FMX103 (1.5% topical minocycline foam) has experts split over the drug’s real-world ability to protect against sunburn, despite...Read More... The post Foamix’s rosacea d...

Buoyed By Phase III Rosacea Success, Foamix Plans Commercial Transition

Market of dermatologists prescribing for rosacea and acne is very focused, so Foamix says it can manage commercialization of topical...   

Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial Evaluating FMX101

Foamix Pharmaceuticals (NASDAQ:FOMX) a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, to...

Foamix's treatment for common skin condition meets late-stage trial goals

Foamix Pharmaceuticals Ltd said on Wednesday its experimental foam treatment for rosacea, a common skin condition that causes acne-like bumps and redness on the face, met the main goals of two late-st...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Foamix Ltd

Foamix Ltd. is a leading developer of topical and mucosal foams for dermatological and gynecological applications. Foamix's state-of-the-art foams provide controlled delivery of a variety of activ...

More Information about "Foamix Ltd" on BioPortfolio

We have published hundreds of Foamix Ltd news stories on BioPortfolio along with dozens of Foamix Ltd Clinical Trials and PubMed Articles about Foamix Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Foamix Ltd Companies in our database. You can also find out about relevant Foamix Ltd Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...


Corporate Database Quicklinks



Searches Linking to this Company Record